Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

Kyoungmin Lee; Kyung-Hun Lee; Dong-Wan Kim; Jeesun Yoon; Yoon Ji Choi; Soohyeon Lee; Ju Won Kim; Kyong Hwa Park; Wonyoung Choi; Youngjoo Lee; Hyewon Ryu; Dong-Hoe Koo; YunGyoo Lee; Hei-Cheul Jeung; Min-Young Lee; Namsu Lee; Myoung Joo Kang; Jieun Lee; Sook Hee Hong; Eun Joo Kang; In Hae Park

doi:10.1002/cac2.70026

Cancer Communications ›› 2025, Vol. 45 ›› Issue (7) : 841 -845. DOI: 10.1002/cac2.70026

LETTER TO THE JOURNAL

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

Author information +

¹. Division of Hematology/Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea

². Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea

³. Division of Hematology/Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea

⁴. Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea

⁵. Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea

⁶. Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁷. Deparment of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

⁸. Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea

⁹. Division of Hematology-Oncology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Republic of Korea

¹⁰. Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

parkih@korea.ac.kr

Show less

History +

PDF

Cite this article

Download citation ▾

Kyoungmin Lee, Kyung-Hun Lee, Dong-Wan Kim, Jeesun Yoon, Yoon Ji Choi, Soohyeon Lee, Ju Won Kim, Kyong Hwa Park, Wonyoung Choi, Youngjoo Lee, Hyewon Ryu, Dong-Hoe Koo, YunGyoo Lee, Hei-Cheul Jeung, Min-Young Lee, Namsu Lee, Myoung Joo Kang, Jieun Lee, Sook Hee Hong, Eun Joo Kang, In Hae Park. Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial. Cancer Communications, 2025, 45(7): 841-845 DOI:10.1002/cac2.70026

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10): 1113–20.

[2]	Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024; 21(9): 675–700.

[3]	Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024; 22(5): 331–57.

[4]	Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554(7691): 189–94.

[5]	Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, et al. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022; 28(7): 1258–67.

[6]	Li B, Gandhi L, Besse B, Jhaveri K, Mazières J, Boni V, et al. FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies. Journal of Thoracic Oncology. 2021; 16(3): S234.

[7]	Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, et al. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2023; 67: 94–101.

[8]	Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024; 25(6): 707–19.

[9]	Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022; 386(3): 241–51.